Cephalon’s New CLL Drug Should Please Patients and Investors (pfblogs.org)
H.S. Ayoub submits: For the first time in seven years, a new therapy for Chronic Lymphocytic Leukemia [CLL] has been cleared in the U.S. by the FDA. Biotech firm Cephalon’s (CEPH) Treanda (bendamustine hydrochloride) was given final approval by the FDA on March 20, only six months after the company submitted the NDA in September of 2007.Complete Story » …
More: continued here